Fig. 4From: Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST studyKey secondary endpoints: a mean percentage of patients with ≥ 50%, ≥ 75%, and 100% reductions in monthly migraine headache days; b LS mean change in the Migraine-Specific Quality of Life Questionnaire Role Function-RestrictiveCI, confidence interval; LS, least squares; SE, standard error. ***p < 0.0001 versus placeboBack to article page